Annual Report

Overview

The report describes BioInvent's 2022 clinical advances, including five proprietary clinical studies and progress for BI-1206, BI-1607, BI-1808 and BT-001. It highlights the Exelixis agreement, SEK 326.1 million in group net sales and strengthened financing. The sustainability section covers the Code of Conduct, environmental controls, employee wellbeing and gender distribution.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Publication date: 6 April 2023
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services